Aventus
Payments companies reported to CMS as associated with Aventus. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Aventus, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Aventus
These are the largest totals companies reported as associated with Aventus. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mehdi Shishehbor | Elyria, OH | Cardiovascular Disease | $52,461.27 |
| Saher Sabri | Washington, DC | Vascular & Interventional Radiology | $40,125.82 |
| Samuel Horr | Nashville, TN | Interventional Cardiology | $33,882.29 |
| Brian Stegman | St Cloud, MN | Interventional Cardiology | $20,642.60 |
| Peter Monteleone | Kyle, TX | Interventional Cardiology | $10,087.20 |
| Joseph Ingrassia | Hartford, CT | Interventional Cardiology | $8,433.05 |
| David O'Connor | Hackensack, NJ | Vascular Surgery | $7,794.83 |
| Christopher Huff | Columbus, OH | Interventional Cardiology | $7,641.77 |
| Daniel Schimmel | Chicago, IL | Interventional Cardiology | $6,269.16 |
| Sirish Kishore | Stanford, CA | Vascular & Interventional Radiology | $5,250.00 |
Prescribed Aventus?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.